tiprankstipranks
In this article:
Blurbs

BioLife Solutions (BLFS) Gets a Buy Rating from KeyBanc

In this article:
In this article:

KeyBanc analyst Paul Knight maintained a Buy rating on BioLife Solutions (BLFSResearch Report) today and set a price target of $30.00. The company’s shares closed last Tuesday at $11.53, close to its 52-week low of $10.74.

According to TipRanks.com, Knight is a 3-star analyst with an average return of 3.2% and a 42.3% success rate. Knight covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Stevanato Group, and IQVIA Holdings.

Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $43.83, which is a 280.8% upside from current levels. In a report issued on April 25, Oppenheimer also upgraded the stock to Buy with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

BioLife Solutions’ market cap is currently $458.8M and has a P/E ratio of -59.60.

Based on the recent corporate insider activity of 139 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.

Read More on BLFS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed